The Use of 5-HTP in the Treatment of Down's Syndrome

PEDIATRICS ◽  
1974 ◽  
Vol 54 (2) ◽  
pp. 165-168
Author(s):  
Phillip Weise ◽  
Richard Koch ◽  
Kenneth N.F. Shaw ◽  
Martin J. Rosenfeld
Keyword(s):  
Down's Syndrome ◽  
Initial Dosage ◽  
Down’S Syndrome ◽  
Clinical Use ◽  
Developmental Quotient ◽  
Rate Of Development ◽  
The Difference ◽  
Age Category ◽  
Treatment Of Down's Syndrome

The clinical use of 5-HTP in the treatment of patients with Down's syndrome was reported by Bazelon and her colleagues in 1967. This approach appeared to offer the hope of improving subnormal development of children with this chromosomal defect. The rationale for the use of 5-HTP is related to its role as the natural biochemical precursor for serotonin (5-hydroxytryptamine). The blood level of this hormone is said to be decreased in Down's syndrome. The present study concerns 26 children with Down's syndrome who were treated with 5-HTP from early infancy until 3 to 4 years of age: 19 completed the course of treatment. DL-5-HTP was given orally with an initial dosage of 0.5 to 1.5 mg/kg/day. The dose was increased stepwise in 1 mg/kg/day increments to a maximum of 5 mg/kg/day. Children were seen by a clinic physician every 1 to 4 months and were assessed by a clinic psychologist every six months. The Gesell Test of Developmental Abilities was used to assess each child's level of development in terms of a total Developmental Quotient (DQ). The psychological findings were analyzed by applying a t test of the difference between independent mean DQs obtained for each age category. The results of this study indicate that long-term systematic use of 5-HTP is not effective in increasing the rate of development of Down's syndrome children.

Informed choice to undergo prenatal screening: a comparison of two hospitals conducting testing either as part of a routine visit or requiring a separate visit

2002 ◽  
Vol 9 (3) ◽  
pp. 109-114 ◽  
Author(s):  
E. Dormandy ◽  
R. Hooper ◽  
S. Michie ◽  
T.M. Marteau
Keyword(s):  
Prenatal Screening ◽  
Down's Syndrome ◽  
Down’S Syndrome ◽  
Informed Choice ◽  
Test Results ◽  
Negative Attitudes ◽  
Multidimensional Measure ◽  
Positive Attitudes ◽  
The Difference ◽  
Study Setting

BACKGROUND: It is not known which of two common methods of conducting prenatal screening best facilitate women making informed choices. OBJECTIVE: To describe rates of informed choice in two hospitals: one where screening for Down’s syndrome was conducted at a routine visit; the other where screening was conducted as part of a separate visit. DESIGN: Prospective descriptive study. SETTING: Two hospitals in England. PARTICIPANTS: 1499 pregnant women offered screening for Down’s syndrome. Outcome measure: A multidimensional measure of informed choice derived from measures of (a) consistency between attitudes towards undergoing the test and uptake and (b) knowledge about the screening test. RESULTS: The proportion of women making an informed choice to accept the test was higher at the routine visit hospital than at the separate visit hospital (41% v 21%, 95% confidence interval (95% CI) of the difference 16% to 25%). The proportions of women making an informed choice to decline the test were similar at the two hospitals (23% at both, 95% CI of the difference -5% to 4%). These results reflect the finding that women with negative attitudes were equally likely to decline the test at each of the two hospitals, whereas women with positive attitudes were more likely to accept the test at the routine visit hospital than at the separate visit hospital. This finding held after adjusting for parity, socioeconomic status, age, and ethnicity. At both hospitals, women with good knowledge were slightly more likely to undergo the test than were women with poor knowledge. This difference disappeared after a similar adjustment. CONCLUSION: Screening conducted as part of a routine visit may be associated with higher levels of informed choice than screening conducted at a separate visit. This finding constitutes a hypothesis for experimental investigation.

scholarly journals Effect of Leucovorin (Folinic Acid) on the Developmental Quotient of Children with Down's Syndrome (Trisomy 21) and Influence of Thyroid Status

PLoS ONE ◽  
2010 ◽  
Vol 5 (1) ◽  
pp. e8394 ◽  
Author(s):  
Henri Blehaut ◽  
Clotilde Mircher ◽  
Aimé Ravel ◽  
Martine Conte ◽  
Veronique de Portzamparc ◽  
...  
Keyword(s):  
Folinic Acid ◽  
Trisomy 21 ◽  
Down's Syndrome ◽  
Down’S Syndrome ◽  
Thyroid Status ◽  
Developmental Quotient

Immunodeficiency and plasma zinc levels in children with Down's syndrome: A long-term follow-up of oral zinc supplementation

1991 ◽  
Vol 58 (2) ◽  
pp. 207-216 ◽  
Author(s):  
A. Stabile ◽  
M.A. Pesaresi ◽  
A.M. Stabile ◽  
M. Pastore ◽  
S.Miceli Sopo ◽  
...  
Keyword(s):  
Zinc Supplementation ◽  
Down's Syndrome ◽  
Down’S Syndrome ◽  
Plasma Zinc ◽  
Long Term Follow Up ◽  
Zinc Levels

Relinquishment for Adoption of Babies with Down's Syndrome: Parents' Response to the Diagnosis and the Role of Health Professionals

2001 ◽  
Vol 25 (2) ◽  
pp. 49-55 ◽  
Author(s):  
Annick-Camille Dumaret ◽  
Dominique Rosset
Keyword(s):  
Health Professionals ◽  
Down's Syndrome ◽  
Down’S Syndrome ◽  
Determining Factors ◽  
Research Findings ◽  
The Impact

Annick-Camille Dumaret and Dominique Rosset present a synthesis of research findings based on a study conducted in France between 1990 and 1996. The project aimed to establish a clearer understanding of why infants with Down's Syndrome were given up for adoption, to evaluate the extent of the phenomenon and its evolution over the long term. It also analysed the impact of the diagnosis on the parents' decision about whether to keep the baby or not and highlighted the determining factors in babies being given up for adoption.

Sign in / Sign up

Export Citation Format

Share Document